One of the two major issues for a drug company, besides gaining market authorisation, is persuading the country in question to reimburse them, that is pay for the drug that the company is attempting to market. But price is the key here, if a drug is priced too low revenues will be compromised, and if priced too high the drug company reduces the chances of reimbursement, severely denting profits.
All countries have different pricing and reimbursement systems; all with a differing emphasis. Some countries have a drug reference pricing system where the price of the drug has to correspond to a basket of prices from other leading countries; some allow a price only based on permitted future profits, and the US alone has a supposedly free market where the drug company is free to set any price. Although, the reality of this ‘free market’ is perhaps not as free as the US system of pricing implies. Also the new Medicare Act 2003 has even more implications for the fate of drug prices in the US healthcare economy and possibly favourable consequences for the future profitability of drug companies in the US market.
It’s Pricing and Reimbursement 2005 / 2006, Evaluating Key Strategic Issues discusses this particular issue at depth and the intricacies of Pricing & Reimbursements system throughout the rest of the developed world. This report will give you insight and clarity into what can be a confusing and contradictory labyrinth and therefore becomes an essential guide of the best method of approaching reimbursement problems. Each chapter not only describes the individual country-specific P&R systems, but also describes new regulatory developments and how these changes will affect future drug pricing and therefore the drug revenues of your company.
A very important aspect of Pricing & Reimbursement concerns the US market, which currently takes 50% of the worlds’ drug revenues. The dominating issue in drug pricing is whether the US will adopt price controls. Such controls now exist in one form or another throughout the rest of the developed world. When will it happen in the US, if at all? This issue is explored at length in this report and what control Medicare/Medicaid will have over future drug pricing in the US is outlined and discussed in detail. Buying Its’ report Pricing and Reimbursement 2005 / 2006, Evaluating Key Strategic Issues will enable a clearer understanding of the large bureaucratic and legislative hurdles that this final stage of drug marketing holds. With 13 Chapters, over 200 pages, including over 20 tables; It’s Pricing and Reimbursement, 2005 will give you clear descriptions of how best to understand and solve important reimbursement issues. It’s Pricing and Reimbursement 2005 / 2006, Evaluating Key Strategic Issues is a vital tool for any drug pricing strategy.
For more information, kindly visit :
http://www.bharatbook.com/
_____________________________________________
